Meeting
2022 ASCO Annual Meeting
Rapid access to biomarker data in a community setting: Integration of next-generation sequencing into routine pathologic workflow.
Authors
Kirstin Perdrizet
University of Toronto, Toronto, ON, Canada
Kirstin Perdrizet , Parneet Kaur Cheema , Andrea Beharry , Joanne Diep , Marco Iafolla , William Raskin , Shaan Dudani , Mary Anne Brett , Blerta Starova , Brian Olsen , Brandon Sheffield
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3143)
DOI
10.1200/JCO.2022.40.16_suppl.3143
Abstract #
3143
Poster Bd #
135
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns in patients with stage IV non-small cell lung cancer (NSCLC) in U.S. community-based oncology practice setting.
First Author: Anthony Sireci
First Author: Mohamed E. Salem
Poster
2014 ASCO Annual Meeting
Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.
First Author: Lindsay Carol Overton